Clinical trials: Clinical Stratification
Appendicitis
Pediatric Appendicitis Risk Calculator (pARC) in Children With Appendix Ultrasounds
Acute appendicitis (AA) is the most common condition requiring emergency surgery in children. At a network of institutions nationwide, a tool called the pediatric appendicitis risk calculator (pARC)1 is being studied to assess…
- Trial name
- NCT03522233
- Where
- 2 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Hemophagocytic Lymphohistiocytoses, Cytokine Storm
Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a rapidly fatal disease caused by immune-dysregulation characterized by hypercytokinemia, with about 30%-40% of patients suffering death in children.
- Trial name
- NCT05491304
- Testing
- Dexamethasone, Etoposide, Ruxolitinib
- Where
- China
- Volunteers
- 400 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Major Depressive Disorder
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Major depressive disorder (MDD) is the most common psychiatric disease worldwide with a huge socio-economic impact. Pharmacotherapy represents the first-line treatment choice; however, only about one third of patients respond to…
- Trial name
- PROMPT (NCT05537558)
- Testing
- Antidepressant
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital Muenster
Inflammatory Bowel Disease, Inflammatory Bowel Disease (IBD)
Automated Clinical Pathway for Inflammatory Bowel Disease Care
Pragmatic randomized controlled trial to evaluate the effect of an electronic medical record-based tool on improving on-time follow up and its effects on inflammatory bowel disease outcomes
- Trial name
- NCT07167836
- Testing
- Electronic medical record-based care pathway
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Texas Southwestern Medical Center
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART C (NCT05745714)
- Testing
- Ruxolitinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
Myocarditis, Ventricular Arrhythmia
Role of Endomyocardial Biopsy and Aetiology-based Treatment in Pediatric Patients with Inflammatory Heart Disease in Arrhythmic and Non-arrhythmic Clinical Presentations: an Integrated Approach for the Optimal Diagnostic and Therapeutic Management (MYOPED)
Myocarditis is a complex inflammatory disease, usually occurring secondary to viral infections, autoimmune processes or toxic agents.
- Conditions
- Myocarditis, Ventricular Arrhythmia, Inflammatory Cardiomyopathy, Genetic Predisposition
- Trial name
- MYOPED (NCT06591260)
- Testing
- support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Scientific Institute San Raffaele
Cardiomyopathy, Hypertrophic
The Chinese Hypertrophic Cardiomyopathy Study(CHCS)
Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. Sudden cardiac death (SCD), heart failure and stroke are the major poor outcomes of HCM.
- Trial name
- CHCS (NCT02696135)
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- China National Center for Cardiovascular Diseases
Leukemia
Efficacy Study of Low-dose Glucocorticoid Prophylaxis for Acute Graft-versus-host Disease(GVHD)
Hematopoietic stem cell transplantation (HSCT) is one of the best, and sometimes the only, option for the treatment of leukemia. However, GVHD rate was still high after haploidentical HSCT.
- Trial name
- NCT01607580
- Testing
- low-dose glucocorticoid Methylprednisolone
- Where
- 2 sites in China
- Volunteers
- 145 people
- Sponsor
- Peking University People's Hospital
Crowding, Tooth, Tipped Tooth or Teeth
Efficacy and Effectiveness of Two Types of Aligners Based on Stratification by Type of Movement
The purpose of this study is to evaluate the biomechanical behaviour of direct-printed and thermoformed aligners in different tooth movements, creating a biomechanical planning protocol based on a stratification of tooth…
- Conditions
- Crowding, Tooth, Tipped Tooth or Teeth, Rotation of Tooth, Malocclusion, Angle's Class
- Trial name
- NCT06516185
- Testing
- direct-printed aligner, thermoformed aligner
- Where
- Spain
- Volunteers
- 114 people
- Sponsor
- Universidad Complutense de Madrid
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART D (NCT05658640)
- Testing
- Trametinib, Dexamethasone, Cyclophosphamide
- Where
- 36 sites in Austria, Belgium and 13 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology
PIK3CA-related Overgrowth Spectrum, CLOVES Syndrome
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth.
- Conditions
- PIK3CA-related Overgrowth Spectrum, CLOVES Syndrome, Klippel Trenaunay Syndrome, Megalencephaly
- Trial name
- COSY (NCT05563831)
- Testing
- national registry
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Juvenile Idiopathic Arthritis
Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA), the most common rheumatologic chronic disease in children, is defined as arthritis persisting for at least 6 weeks with no known cause in a patient under the age of 16.
- Trial name
- NCT06007456
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Burlo Garofolo
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
This phase II trial compares the effect of using risk-based stratification to guide surgical management to the usual approach in treating cutaneous melanoma, atypical Spitz/Spitzoid tumors or other atypical melanocytic tumors…
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm
- Trial name
- NCT07621614
- Testing
- Biospecimen Collection, Chest Radiography, Computed Tomography
- Where
- 13 sites in United States
- Volunteers
- 51 people
- Sponsor
- Children's Oncology Group
Stem Cell Transplant Complications
Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment of malignant hematopoietic diseases. However, poor hematopoietic reconstitution including poor graft function (PGF) and prolonged isolated…
- Trial name
- NCT03967665
- Testing
- N-acetyl-L-cysteine
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
Lower Respiratory Tract Infection (LRTI), Pneumonia
Optimising Antibiotic Use for Paediatric Lower Respiratory Tract Infections in Africa
Lower respiratory tract infections (LRTIs) remain a leading cause of hospitalisation and death among young children in Africa. Although viral infections account for a substantial proportion of LRTIs, antibiotics are frequently…
- Conditions
- Lower Respiratory Tract Infection (LRTI), Pneumonia, Bronchopneumonia, Bronchiolitis
- Trial name
- BEACON (NCT07841691)
- Testing
- CRP- and PREPARE-guided Antibiotic Prescription
- Where
- South Africa
- Volunteers
- 400 people
- Sponsor
- University of Witwatersrand, South Africa
Antibiotic Allergy
Penicillin Allergy Risk-Stratification and Delabeling of Low-Risk Patients
Children are often reported to have antibiotics allergies, with approximately 10% of the US population labeled as allergic to an antibiotic, however, recent studies have demonstrated that the majority of symptoms reported as an…
- Trial name
- NCT05561777
- Testing
- Physician-targeted CDS tool for PCN allergy delabeling
- Where
- United States
- Sponsor
- Vanderbilt University Medical Center
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
Cardiovascular Diseases
Precision Medicine Study on Cardiovascular Disease (PRECISE)
Cardiovascular diseases are the leading cause of death in China and have become a financial burden on society under the traditional medical model.
- Trial name
- PRECISE (NCT04434911)
- Where
- China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- China National Center for Cardiovascular Diseases
Covid19
COVID19 Severity Prediction and Health Services Research Evaluation
1. Objectives: 1.-To create risk stratification scales of poor evolution in patients infected by SARS-CoV-2. 2.-Evaluate the accessibility and equity that these patients have had in the different care processes, diagnostic and…
- Trial name
- NCT04463706
- Testing
- Predictors adverse evolution, Predictors of health care provide
- Where
- Spain
- Volunteers
- 380,000 people
- Sponsor
- Hospital Galdakao-Usansolo
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL.
- Conditions
- Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Trial name
- HEM-iSMART B (NCT05751044)
- Testing
- Dasatinib, Venetoclax, Dexamethasone
- Where
- 33 sites in Austria, Belgium and 12 more
- Volunteers
- 26 people
- Sponsor
- Princess Maxima Center for Pediatric Oncology